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Abstract: Pertaining to the female population in the USA, breast cancer is the leading cancer in terms of annual incidence rate and, 
in terms of mortality, the second most lethal cancer. There are currently no biomarkers available that can predict which breast cancer 
patients will respond to chemotherapy with both sensitivity and specificity . 80%, as mandated by the latest FDA requirements. In this 
study, we have developed a prognostic biomarker model (complex mathematical function) that—based on global gene expression analy-
sis of tumor tissue collected during biopsy and prior to the commencement of chemotherapy—can identify with a high accuracy those 
patients with breast cancer (clinical stages I–III) who will respond to the paclitaxel-fluorouracil-doxorubicin-cyclophosphamide chemo-
therapy and will experience pathological complete response (Responders), as well as those breast cancer patients (clinical stages I–III) 
who will not do so (Non-Responders). Most importantly, both the application and the accuracy of our breast cancer prognostic biomarker 
model are independent of the status of the hormone receptors ER, PR, and HER2, as well as of the ethnicity and age of the subjects. 
We developed our prognostic biomarker model with 50 subjects [10 responders (R) and 40 non-responders (NR)], and we validated it 
with 43 unknown (new and different) subjects [10 responders (R) and 33 non-responders (NR)]. All 93 subjects were recruited at five 
different clinical centers around the world. The overall sensitivity and specificity of our prognostic biomarker model were 90.0% and 
91.8%, respectively. The nine most significant genes identified, which comprise the input variables to the mathematical function, are 
involved in regulation of transcription; cell proliferation, invasion, and migration; oncogenesis; suppression of immune response; and 
drug resistance and cancer recurrence.
Keywords: breast cancer, biomarkers, prognostic biomarker models, treatment response, global gene expression analysis, systems 
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Introduction
In the USA, breast cancer is the leading cancer in terms 
of annual incidence rate (~207,090 new cases/year) 
and,  in  terms  of  mortality,  the  second  most  lethal 
cancer (~39,840 deaths/year).1,2 Treatment may entail 
lumpectomy or mastectomy and removal of some of 
the axillary lymph nodes, and it may involve chemo-
therapy (with taxol or other chemotherapeutic agents), 
before or after surgery, hormone therapy, or radiation.1 
There are currently no biomarkers available that can 
predict  which  breast  cancer  patients  will  respond 
to  chemotherapy  with  both  sensitivity  and  specific-
ity . 80%, as mandated by the latest FDA   requirements. 
It follows, therefore, that a prognostic test that could 
identify  with  a  high  accuracy  those  breast  cancer 
patients who will respond to chemotherapy, as well 
as those patients who will not do so, would constitute 
significant progress against this   disease. More specifi-
cally, such a prognostic test would be invaluable in: 
(1) providing the physicians with the ability to iden-
tify responders from non-responders at the outset (at 
the time of the biopsy and prior to the commencement 
of chemotherapy), (2) providing alternative therapies 
to non-responders of chemotherapy, and (3) helping 
pharmaceutical companies to test and develop new 
analogs of chemotherapeutic agents that may be more 
effective for the non-responders.
In  this  study,  by  analyzing  the  global  gene 
expression data of the tumor tissue obtained dur-
ing biopsy (and, therefore, prior to the administra-
tion of chemotherapy) from 93 patients with breast 
cancer (clinical stages I–III), we developed a prog-
nostic  biomarker  model  that  was  able  to  identify 
with  a  high  accuracy  (overall  sensitivity:  90.0% 
and overall specificity: 91.8%) both the responders 
(R) and the non-responders (NR) to the paclitaxel 
and  fluorouracil-doxorubicin-cyclophosphamide 
(T/FAC) chemotherapy, regardless of the status of 
the  estrogen  (ER),  progesterone  (PR),  and  HER2 
hormone receptors of the subjects. We developed 
our prognostic biomarker model using 50 patients 
[10 responders (R) and 40 non-responders (NR)], 
and  we  validated  it  with  43  unknown  patients 
[10  responders  (R)  and  33  non-responders  (NR)] 
that were new and different from those 50 used in 
the development of the model.
Our prognostic biomarker model (F1) is a com-
plex mathematical function of nine genes. Those nine 
genes are therefore deemed highly significant in the 
process of the response to the T/FAC treatment on the 
part of breast cancer patients. Of those nine genes, 
one has been known to induce tumorigenesis by alter-
ing cell-cycle progression; two genes are involved 
in  cell  proliferation,  invasion,  and  migration;  one 
gene is involved in immune response; two genes are 
known to interact directly with BRCA1 and BRCA2; 
one gene is known to interact directly with c-MYC 
and another with HRAS; and two genes are involved 
in lipid metabolism.
Materials and Methods
Data acquisition and clinical sample 
information
We used the raw intensity microarray data (CEL files) 
for 20 subjects that responded to chemotherapy and 
for 73 subjects that did not respond to chemotherapy 
as posted by Tabchy et al3 at the GEO (Gene Expres-
sion  Omnibus)  of  the  NCBI  (National  Center  for 
  Biotechnology Information) [ID: GSE20271].
Briefly, according to Tabchy et al,3 patients with 
breast  cancer  (clinical  stages  I–III)  were  recruited 
in  five  different  clinical  centers  around  the  world 
[M. D. Anderson Cancer Center, Houston, TX, USA; 
Lyndon  B.  Johnson  General  Hospital,    Houston, 
TX,  USA;  Instituto  Nacional  de  Enfermedades 
  Neoplasicas, Lima, Peru; Centro Medico Nacionalde 
Occidente, Guadalajara, Mexico; and Grupo Espanol 
de Investigacion en Cancer de Mama, Spain]. All sub-
jects first underwent biopsy, and tumor tissue obtained 
thus was analyzed for global gene expression using the 
GeneChip array U133A by Affymetrix.   Histological 
diagnosis of invasive cancer and status of the ER, PR, 
and HER2 receptors were also determined from tis-
sue obtained from the biopsy. Following biopsy, all 
subjects  were  treated  with  chemotherapy  compris-
ing the following drugs and dosage protocol: weekly 
paclitaxel (80 mg/m2/wk) × 12 courses followed by 
5-  fluorouracil (500 mg/m2), doxorubicin (50 mg/m2), 
and  cyclophosphamide  (500  mg/m2)  all  on  day  1 
repeated in 21-day cycles × 4 courses. Following the 
completion  of  the  aforementioned  chemotherapy 
(T/FAC),  all  subjects  underwent  surgery  (modi-
fied radical mastectomy or lumpectomy and senti-
nel lymph node biopsy or axillary node dissection) 
in order to determine whether a subject experienced 
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whether  residual  invasive  cancer  was  still  present. 
  Pathological complete response to chemotherapy was 
defined as the absence of any residual invasive cancer 
at the breast site and at the nearest axillary lymph node 
site. Ninety three subjects were able to complete the 
aforementioned treatment protocol in terms of dosage 
and frequency (number of administered courses) of 
taxol and the other drugs of the T/FAC treatment. Of 
those 93 subjects, 20 responded to the T/FAC treat-
ment and had no residual invasive cancer at the end of 
the six-month course, whereas the remaining 73 did 
not do so. For more demographic and clinical details, 
please see the study by Tabchy et al.3
Discovery and validation studies
Of  the  total  93  subjects,  we  randomly  selected 
50  of  them  [10  responders  (R)  and  40  non-
  responders (NR)] for the development and training 
of  our  prognostic  biomarker  model.  The  remain-
ing  43    subjects  [10  responders  (R)  and  33  non-
  responders (NR)] constituted the unknown subjects 
with  which  our  prognostic  biomarker  model  was 
tested.  This  validation  method  provided  us  with 
the means to test our prognostic biomarker model 
with 43 new and real unknowns that were different 
from  the  subjects  used  for—and,  therefore,  com-
pletely extraneous to—the development and train-
ing of the model. The   proportions of the   clinical 
stages (I–III) in the total set of 93 subjects were 
  maintained  in  both  the  discovery  and  validation 
subsets of subjects. Moreover, subjects with all pos-
sible combinations of receptor classifications (ER, 
PR, and HER2) were included in both the discovery 
and the validation study with approximately equal 
  proportions. Table 1 shows all clinical information 
regarding  the  stage  and  the  receptor  status  of  all 
93 subjects, including that of the subjects misclassi-
fied by our prognostic biomarker model.
Statistical methods
We processed the original raw intensity data (CEL 
files)  using  the  Expression  Console  software  by 
Affymetrix and choosing the RMA algorithm (510K 
FDA approved) with the standard settings.
In order to reduce the dimensionality of the data 
and zero in on those variables (transcripts) that are 
most significant in the process of treatment-response 
in the case of breast cancer patients, we applied our 
bioinformatic methods that we have developed, pre-
sented, and explained in a great detail in our previ-
ous  studies.4–8  Briefly,  we  performed  ROC  curve 
analysis in order to assess the discriminating capabil-
ity of all variables with respect to our two groups, 
namely, R (responders) and NR (non-responders). In 
the final round, we selected only those variables with 
an AUC $ 0.770. Fourteen variables fulfilled this 
Table 1. clinical information pertaining to the stage and receptor status of all 93 subjects, including that of the subjects 
misclassified by the F1 prognostic biomarker model. 
Group no. of 
subjects
stage 
I
stage 
II
stage 
III
Unknown 
stage
eR(+) eR(-) pR(+) pR(-) HeR2(+) HeR2(-)
A. Discovery
r 10 0 2 5 3 2 8 1 9 3 7
nr 40 6 16 14 4 27 13 25 15 4 36
B. Validation
r 10 0 1 7 2 2 8 1 9 4 6
nr 33 5 13 10 5 20 13 17 16 4 29
C. Misclassified subjects
Discovery
 r 1 0 0 0 1 1 0 0 1 0 1
  nr 4 1 1 2 0 2 2 2 2 0 4
Validation
 r 1 0 0 1 0 0 1 0 1 1 0
  nr 2 0 0 0 2 0 2 0 2 0 2
notes: The information and the results shown in Table 1 provide evidence that the accuracy of the F1 prognostic biomarker model is independent of 
the receptor status of the subject. A. clinical information pertaining to the stage and receptor status of the 50 subjects [10 responders (r) and 40 non-
responders (nr)] used in the discovery study. B. clinical information pertaining to the stage and receptor status of the 43 unknown subjects [10 responders 
(r) and 33 non-responders (nr)] used in the validation study. c. clinical information pertaining to the stage and receptor status of all 8 subjects (5 in the 
discovery study and 3 in the validation study) misclassified by the F1 prognostic biomarker model.nikas et al
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  criterion, and they constituted the final pool of the 
most significant variables.
Generation of the F1 Super Variable (mathemati-
cal function): From the aforementioned 14 most sig-
nificant variables, 9 became the input variables to the 
complex mathematical function F1, also referred to 
here as super variable. We should point out that one 
other  super  variable  was  generated  employing  the 
remaining of the aforementioned 14 most significant 
variables, but, following final assessment, it proved 
to be not as robust as the F1, and it is consequently not 
presented here. The 9 input variables (transcripts) to 
the F1 super variable correspond to 9 different genes. 
The F1 super variable, therefore, is a function of the 
following  9  genes,  presented  here  in  alphabetical 
order:
 F 1 =   f ( CCND1, CELSR1, DKFZp566H0824, 
FAAH, IGKV1-5, LAMA5, OXCT1, RARA, 
UBE2J1)
  (1)
The  F1  super  variable  (complex  mathematical 
function) (Equation 1) constitutes the final prognos-
tic biomarker model of treatment response of breast 
cancer patients (clinical stages I–III), and its 9 input 
variables (genes) are listed in Table 2, along with 
their name, relative differential expression, and other 
properties.
computer programs
Computer programs were written using MATLAB 
R2011b  by  The  MathWorks,  Inc.,  Natick,  MA, 
USA.
Results
Discovery study
As was mentioned earlier, from the total number of 
93 subjects [20 responders (R) and 73 non-responders 
(NR)] used in this study, we randomly selected 50 sub-
jects [10 responders (R) and 40 non-responders (NR)] 
for the development and training of the prognostic 
biomarker model (F1); and we will henceforward refer 
to those 50 subjects as the 50 original subjects. After 
the development of the prognostic biomarker model, 
we assessed its accuracy using the   aforementioned 
50  original  subjects,  which  were  employed  for  its 
development. This constitutes an important first step 
in the assessment of a prognostic test.
The cut-off score of the F1 prognostic biomarker 
model  was  determined  by  taking  into  account  the 
results  of  the  following  two  analyses:  (1)  calcula-
tion of the optimal point on the ROC curve based 
on the 50 scores of the 50 original subjects used in 
the discovery study [optimal point is defined as the 
point with the highest sensitivity and the lowest false 
positive rate (1-specificity)] and (2) calculation of the 
99.99% confidence intervals for the mean F1 scores of 
the two groups (R and NR) and their respective stan-
dard deviations. Based on that, the cut-off score of the 
F1 model was determined to be 4.6683. If a subject 
has an F1 score less than 4.6683, then that subject is 
classified as an R (responder); otherwise ($4.6683), 
that subject is classified as an NR (non-responder). 
As  can  be  seen  from  Figure  1,  the  F1  model  cor-
rectly identified (9/10) R subjects and (36/40) NR 
subjects. Assuming that we are interested in identify-
ing the responders (R) to the T/FAC chemotherapy, 
our target group is the R group and our reference 
group is the NR group. It follows, then, that for the 
discovery  study,  the  F1  model  exhibited  a  sensi-
tivity = 9/10 = 0.900 and a specificity = 36/40 = 0.900. 
Figure  1  and  Table  3  show  all  pertinent  statisti-
cal results of the F1 prognostic biomarker model in 
  connection with the discovery study in great detail.
Validation study
As was mentioned earlier, from the total number of 
93 subjects [20 responders (R) and 73 non-responders 
(NR)] used in this study, we had randomly segregated 
43 subjects [10 responders (R) and 33 non-responders 
(NR)] for the sole and express purpose of testing our 
prognostic biomarker model. Those 43 unknown sub-
jects were completely extraneous to the model, that is 
to say they were new and different from the original 
50 subjects used for the development of the model, 
and they had never before been encountered by it. 
This, validation by unknown and different subjects, 
constitutes the most important test in the assessment 
of a prognostic test.
As can be seen from Figure 2 and Table 4, our prog-
nostic biomarker model (F1) correctly identified (9/10) 
R subjects and (31/33) NR subjects from the total of 43 
unknown subjects used in the validation study. More 
specifically, 9/10 R subjects had F1 scores that were less 
than the 4.6683 cut-off value, and 31/33 NR subjects had 
F1 scores that were $4.6683. Therefore, in   connection Prognosis of treatment response in breast cancer
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with  the  validation  study,  the  sensitivity  of  the  F1 
prognostic model was (9/10) = 0.900, and the specificity 
was (31/33) = 0.939.
Table 4, in addition to other pertinent statistical 
results of our prognostic biomarker model, shows the 
observed mean F1 scores of the two groups (R and NR) 
of the 43 unknown subjects in the validation study. 
As can be seen, both of those group mean scores, as 
observed in the validation study with the 43 unknown 
subjects, fall within the 99.99% confidence intervals 
of the respective group mean scores as predicted in 
the discovery study (Table 3).
Overall prognostic biomarker model 
performance
If  we  combined  the  discovery  study  results  with 
those of the validation study, then the overall perfor-
mance of our F1 prognostic biomarker model would 
be as   follows. Overall sensitivity = 0.900 (18/20 R 
subjects) and overall specificity = 0.918 (67/73 NR 
subjects). Figure 3 and Table 5 depict those over-
all results, along with additional pertinent statistical 
results of the F1 prognostic biomarker model.
Significant genes
In connection with the aforementioned 9 significant 
genes that constitute the input variables to the F1 func-
tion (Equation 1), we conducted an   Ingenuity Path-
way Analysis (IPA) search. We sought to ascertain 
information about those 9 genes pertaining to their 
known  interactions  with  other  genes;  their  known 
interactions with drugs, chemicals, and/or hormones; 
and their known associations with various types of 
cancer as derived from the findings of scientific, peer-
reviewed studies. The IPA search results are listed in 
Table 2, along with the direction of the statistically 
significant  differential  expression  (over-expression 
or  under-expression)  of  those  9  genes  in  the  NR 
group (non-responders) relative to that of the R group 
(responders).
The CCND1 (also cyclin D1) gene encodes a pro-
tein that belongs to the cyclin family, the members of 
which are regulators of CDK kinases.   Overexpression 
of the CCND1 gene, which alters cell cycle progression, 
has been observed in a variety of tumors and may con-
tribute to tumorigenesis. Moreover, the CCND1 gene 
has been observed to interact with the BRCA1 and 
BRCA2 genes, known to be   familial breast and ovarian 
cancer  susceptibility  genes.9,10    Over-  expression  of 
CCND1 has been shown to play a crucial role in the 
development and progression of several types of can-
cers,  such  as  breast,  esophageal,  bladder,  and  lung 
cancer.11–15 Furthermore, and more importantly, over-
expression of CCND1 has been linked to the develop-
ment of resistance to endocrine drugs in breast cancer 
cells.11,16,17 Over-  expression of CCDN1 has also been 
shown  to  contribute  to  the    progression  of  breast 
tumor cells to invasive   carcinomas.18 Those findings 
are in agreement with our results: we found that the 
CCND1 gene was significantly over-  expressed in the 
NR group (non-  responders) relative to the R group 
(responders) (Table 2).
The LAMA5 (laminin, alpha 5) gene encodes a 
protein that belongs to the alpha subfamily of lami-
nin  proteins,  which  constitute  a  major  component 
of  basement  membranes,  and  which  affect  tissue 
development  in  many  organs.  Over-expression  of 
the LAMA5 gene has been observed in various types 
of cancer, such as glioma, melanoma, hepatocellu-
lar carcinoma, lung adenocarcinoma, breast cancer, 
ovarian  cancer,  etc.,  especially  in  connection  with 
tumor cell migration and invasiveness.19–24 In addi-
tion to oncogenesis and metastatic colonization, over-
expression of laminin has been linked to cytotoxic 
drug resistance in the case of lung cancer cell lines.25 
Furthermore, in the case of breast cancer cells, it has 
been shown that over-expression of laminin inhibits 
estrogen action and leads to resistance to hormonal 
drugs without the loss of hormone receptors on the 
part of the breast cancer cells.23 The above findings 
are  in  accord  with  our  results:  we  found  that  the 
LAMA5 gene was significantly over-expressed in the 
NR group (non-responders) relative to the R group 
(responders) (Table 2).
The  gene  FAAH  (fatty  acid  amide  hydrolase) 
encodes a protein that is responsible for the hydroly-
sis of a number of primary and secondary fatty acid 
amides. In connection with cancer, it has been observed 
that over-expression of the FAAH gene resulted in 
cell invasion and cell migration in prostate carcinoma 
cells.26 Moreover, tumor over-expression of FAAH 
has been associated with prostate cancer severity and 
outcome,27 and it has been shown that anti-proliferative 
effects could be observed in prostate cancer cell lines 
by  inhibiting  the  FAAH  enzyme.28  In  connection 
with breast cancer, and more specifically regarding nikas et al
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  treatment response, it has been observed that FAAH 
was significantly over-expressed in the subjects that 
failed  to  respond  to  the T/FAC  treatment.29 Those 
findings are in agreement with those of our study: 
we found that the FAAH gene was significantly over-
  expressed in the NR group (non-responders) relative 
to the R group (responders) (Table 2).
We  should  point  out  here  that  in  our  previous 
study on treatment response in ovarian cancer,5 one 
of the three gene networks we discovered to play a 
significant role in the response to the taxol/platinum 
chemotherapy  and  survival  also  pertained  to  lipid 
breakdown metabolism (LYPLA2 and OSBPL8), and 
that strengthens our hypothesis in that study, namely, 
that aggressive tumor cells effect extensive remod-
eling  of  lipid  metabolism,  presumably  for  energy 
purposes.
The  RARA  gene  encodes  a  protein  (retinoic 
acid  receptor  alpha)  that  regulates  transcription. 
In the case of acute promyelocytic leukemia, over-
  expression of RARA has been shown to induce cell 
proliferation via direct up-regulation of c-MYC in 
mice.30    Over-expression  of  RARA  has  also  been 
observed  in  human  ovarian  tumor  cells.31  In  con-
nection with human breast cancer cells, it has been 
widely observed that the expression of ER receptor 
α and that of RARA are coordinated; more specifi-
cally,  over-expression  of  the  former  induces  over-
expression of the latter in ER-positive breast cancer 
cells.32,33 More interestingly, however, regarding our 
findings, it has also been observed that the crucial 
biological effects exerted by RARA on human breast 
cancer cells are mediated regardless of the ER status 
of those cells.34,35 Those findings are in agreement 
with those of our study: we found that the RARA gene 
was  significantly  over-expressed  in  the  NR  group 
(non-responders) relative to the R group (responders) 
(Table 2).
The  CELSR1  (cadherin,  EGF  LAG  seven-pass 
G-type receptor 1) gene encodes a protein that is a mem-
ber of the flamingo subfamily, which is part of the cad-
herin superfamily. The flamingo cadherins are located 
at the plasma membrane and are thought to be recep-
tors involved in contact-mediated cell   communication. 
In squamous cell carcinoma cells, it has been shown 
that over-expressed G protein-coupled receptor pro-
teins,  via  communication  with  EGFR  (epidermal 
growth factor receptor) signaling systems, induce cell nikas et al
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Figure  1.  Scatter  plot  and  bar  graph  of  all  50  original  subjects 
[10 responders (r) and 40 non-responders (nr)] used in the discovery 
study in connection with the F1 prognostic biomarker model.
notes:  As  can  be  seen,  9/10  r  subjects  [responders  (green  color)] 
had  F1  scores  lower  than  the  determined  cut-off  score  of  4.6683  and 
were therefore identified correctly by the F1 prognostic biomarker model 
[sensitivity = 9/10 = 0.900]. regarding the nr group [non-responders (red 
color)], 36/40 subjects had F1 scores greater than the determined cut-off 
score of 4.6683 and were therefore identified correctly by the F1 prognostic 
biomarker model [specificity = 36/40 = 0.900]. For the discovery study, the 
mean F1 score of the 10 r subjects (responders) was 4.4528 (top of the 
green bar) and their standard deviation (whiskers above or below the top of 
the green bar) was 0.3156. The mean F1 score of the 40 nr subjects (non-
responders) was 5.2833 (top of the red bar) and their standard deviation 
(whiskers above or below the top of the red bar) was 0.5074. The significance 
level was set at α = 0.001 (two-tailed), and the probability of significance for 
the F1 was P = 1.06 × 10−5 (independent t-Test with T-value = 4.9195). The 
F1 is parametrically distributed with respect to both groups.
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Figure 2. Scatter plot and bar graph of all 43 unknown (new and different) 
subjects [10 responders (r) and 33 non-responders (nr)] used in the 
validation study in connection with the F1 prognostic biomarker model.
notes:  As  can  be  seen,  9/10  r  subjects  [responders  (green  color)] 
had  F1  scores  lower  than  the  determined  cut-off  score  of  4.6683  and 
were therefore identified correctly by the F1 prognostic biomarker model 
[sensitivity = 9/10 = 0.900]. regarding the nr group [non-responders (red 
color)], 31/33 subjects had F1 scores greater than the determined cut-off 
score of 4.6683 and were therefore identified correctly by the F1 prognostic 
biomarker model [specificity = 31/33 = 0.939]. For the validation study, the 
mean F1 score of the 10 r subjects (responders) was 4.3766 (top of the 
green bar) and their standard deviation (whiskers above or below the top of 
the green bar) was 0.2041. The mean F1 score of the 33 nr subjects (non-
responders) was 5.3028 (top of the red bar) and their standard deviation 
(whiskers above or below the top of the red bar) was 0.5476. The significance 
level was set at α = 0.001 (two-tailed), and the probability of significance for 
the F1 was P = 5.83 × 10−6 (independent t-Test with T-value = 5.2029). The 
F1 is parametrically distributed with respect to both groups.
Table 3. Statistical results of the F1 prognostic biomarker model in the discovery study {identification of the 50 original 
  subjects [10 responders (r) and 40 non-responders (nr)]}.
prognostic  
test
ROc AUc 95% cI of  
ROc AUc
T-value P  
(2-tailed) 
α = 0.001
R group 
[99.99% cI of mean] 
(sD)
nR group 
[99.99% cI of mean] 
(sD)
Discovery study
F1 0.9425 [0.8159, 0.9829] 4.9195 1.06 × 10−5 [4.1611, 4.7981] [5.0103, 5.5300] 
(0.3156) (0.5074)
notes: The ROC AUC value, the 95% confidence interval of the ROC AUC Value, the T value and probability of significance (P) of the independent t-Test, 
the 99.99% confidence interval for the mean score of the R group (Responders) and that of the NR group (Non-Responders), along with their respective 
standard deviations, of the F1 prognostic biomarker model in the discovery study are shown.
proliferation and migration.36 In the case of breast can-
cer cells, it has been observed that CELSR1 interacts 
with estrogen receptor (ER).37 Our findings agree with 
those observations: the CELSR1 gene was significantly 
over-expressed in the NR group (non-responders) rela-
tive to the R group (responders) (Table 2).
The  IGKV1-5  (immunoglobulin  kappa  variable 
1–5) gene encodes a protein whose molecular func-
tion is antigen binding, and which is involved in com-
pliment activation, innate immune response, and in 
regulation of immune response, in general. Although 
little is known about the exact function of IGKV1-5, 
it has been shown that it is expressed in leukocytes in 
human peripheral blood,38 and that various types of 
cancer cells effect significant reduction of the expres-
sion of immune-response related genes, such as those 
involved in antigen presentation pathway,39 genes in 
the B-cell receptor complex,40 genes in the human leu-
kocyte antigen (HLA) class,41 etc. More specifically, 
in connection with breast cancer, it has been observed Prognosis of treatment response in breast cancer
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Table 4. Statistical results of the F1 prognostic biomarker model in the validation study {identification of the 43 unknown 
subjects [10 responders (r) and 33 non-responders (nr)], which were new and different from the 50 original subjects}.
prognostic  
test
ROc AUc sensitivity Specificity T-value P (2-tailed) 
α = 0.001
R group 
Mean ± sD
nR group 
Mean ± sD
Validation study
F1 5.83 × 10−6 4.3766 ± 0.2041 5.3028 ± 0.5476
notes: The ROC AUC value, the sensitivity, the specificity, the T value and probability of significance (P) of the independent t-Test, and the mean score 
of the r group (responders) and that of the nr group (non-responders), along with their respective standard deviations, of the F1 prognostic biomarker 
model in the validation study are shown. As can be seen, both of those group mean scores, as observed in the validation study with the 43 unknown 
subjects, fall within the 99.99% confidence intervals of the respective group mean scores as predicted in the discovery study (Table 3).
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Figure 3. Scatter plot and bar graph of all 93 subjects [20 responders 
(r) and 73 non-responders (nr)] used in the entire study (discovery and 
validation) in connection with the F1 prognostic biomarker model.
notes: As can be seen, 18/20 r subjects [responders (green color)] 
had F1 scores lower than the determined cut-off score of 4.6683 and 
were therefore identified correctly by the F1 prognostic biomarker model 
[sensitivity = 18/20 = 0.900]. regarding the nr group [non-responders 
(red color)], 67/73 subjects had F1 scores greater than the determined 
cut-off score of 4.6683 and were therefore identified correctly by the F1 
prognostic biomarker model [specificity = 67/73 = 0.918]. The mean F1 
score of the 20 r subjects (responders) was 4.4148 (top of the green 
bar) and their standard deviation (whiskers above or below the top of 
the green bar) was 0.2617. The mean F1 score of the 73 nr subjects 
(non-responders) was 5.2921 (top of the red bar) and their standard 
deviation (whiskers above or below the top of the red bar) was 0.5223. 
The significance level was set at α = 0.001 (two-tailed), and the probability 
of significance for the F1 was P = 1.36 × 10−10 (independent t-Test with 
T-value = 7.2454). The F1 is parametrically distributed with respect to 
both groups.
that significant down-regulation of immune-response 
related genes was significantly associated with tumor 
progression, nodal involvement, lymphatic invasion, 
and risk of breast cancer reccurence.41 Those find-
ings are in accord with our results: we found that the 
IGKV1-5 gene was significantly under-expressed in 
the NR group (non-responders) relative to the R group 
(responders) (Table 2).
The Affymetrix HG-U133 A probe set 207470_
at  corresponds  to  DKFZp566H0824  (hypothetical 
LOC54744). According to our results, this unknown 
gene was significantly over-expressed in the NR group 
(non-responders) relative to the R group (responders) 
(Table 2).
The  UBE2J1  (ubiquitin-conjugating  enzyme  E2, 
J1, U) gene encodes a protein that is a member of the 
E2 ubiquitin-conjugating enzyme family. The modi-
fication  of  proteins  with  ubiquitin  is  an  important 
cellular  mechanism  that  targets  abnormal  or  short-
lived  proteins  for  degradation.  It  has  been  shown 
that BRCA1, via its binding to UBE2J1, as well as to 
other members of the E2 family, directs the synthesis 
of specific polyubiquitin chain linkages.42 Given that 
BRCA1 functions as tumor suppressor and plays a role 
in DNA damage repair,43 it follows that an abnormal 
down-regulation of BRCA1 would most likely entail a 
down-regulation of UBE2J1. That would be consistent 
with our findings: the UBE2J1 gene was significantly 
under-expressed  in  the  NR  group  (non-responders) 
relative to the R group (responders) (Table 2).
The OXCT1 (3-oxoacid CoA transferase 1) gene 
encodes a protein that is a mitochondrial matrix enzyme 
and plays a central role in ketone   metabolism. Among 
other biological processes, OXCT1 is involved in adi-
pose tissue development and cellular lipid metabolism. 
It has been observed that HRAS, a well-known onco-
gene involved in many different types of cancer, sup-
presses the expression of OXCT1.44 In connection with 
breast cancer, it has been shown that 69% of breast can-
cer tumors exhibit an over-expression of HRAS, which 
is associated positively with disease progression and 
lymph node involvement and negatively with response to 
treatment.45 It has also been shown that over-expression 
of HRAS in breast cancer tumors can be constitutively 
mediated via deregulation of HER2, ER, EGFR, and 
other receptors.46–48 That, therefore, over-expression of 
HRAS in   aggressive breast tumor cells leads to sup-
0.9788 0.9000 0.9394 5.2029nikas et al
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Table 5. Overall statistical results of the F1 prognostic biomarker model with respect to both the discovery and the validation 
studies combined {identification of 93 subjects [20 responders (R) and 73 non-responders (NR)]}. 
prognostic  
test
ROc AUc sensitivity Specificity T-value P (2-tailed) 
α = 0.001
R group 
Mean ± sD
nR group 
Mean ± sD
Overall results (discovery and validation studies)
F1 0.9616 0.9000 0.9178 7.2454 1.36 × 10−10 4.4148 ± 0.2617 5.2921 ± 0.5223
notes: The overall ROC AUC value, the overall sensitivity, the overall specificity, the T value and probability of significance (P) of the independent t-Test, 
and the mean score of the r group (responders) and that of the nr group (non-responders), along with their respective standard deviations, of the 
F1 prognostic biomarker model with respect to both the discovery and the validation studies combined are shown.
pression  of  the  expression  of  OXCT1  accords  with 
our finding: the OXCT1 gene was significantly under-
  expressed in the NR group (non-  responders) relative to 
the R group (responders) (Table 2).
Discussion
To the best of our knowledge, we are not aware of 
the existence of any prognostic tests that can predict 
which breast cancer patients will respond to chemo-
therapy with both sensitivity and specificity . 80%, 
as mandated by the latest FDA requirements. Hav-
ing  employed  50  subjects  [10  responders  (R)  and 
40 non-responders (NR)], we were able to develop 
a prognostic test that—based on global gene expres-
sion analysis of tumor tissue collected during biopsy 
and prior to the commencement of chemotherapy—
can identify with a high accuracy those patients with 
breast cancer (clinical stages I–III) who will respond 
to  the  T/FAC  chemotherapy  and  will  experience 
pathological  complete  response  (Responders),  as 
well as those breast cancer patients (clinical stages 
I–III) who will not do so (Non-Responders). Follow-
ing validation with 43 unknown (new and different) 
subjects [10 responders (R) and 33 non-responders 
(NR)], our prognostic test (F1) exhibited an overall 
sensitivity  =  0.900  (18/20  R  subjects)  and  overall 
specificity = 0.918 (67/73 NR subjects). Given the 
relatively small number of responders in this study 
(20 R vs. 73 NR), it stands to reason that the robust 
performance of our prognostic test should be further 
tested using a wider pool of subjects not only in terms 
of a larger number of responders but also in terms 
of  demographics,  family  history,  and  syndromic   
associations.
Furthermore, we are equally unaware of the exis-
tence of any prognostic tests that can predict which 
breast cancer patients will respond to chemotherapy 
with both sensitivity and specificity $ 90% and, at 
the same time, regardless of the status of the three 
hormone receptors (ER, PR, and HER2); and that 
constitutes the highest contribution of our study. As 
can be seen from the information and results shown 
in Table 1, our prognostic test with both sensitiv-
ity and specificity $ 90% is applicable, and can be 
administered, to all breast cancer patients indepen-
dently of the status of the hormone receptors ER, 
PR, and HER2, as well as of the ethnicity and age 
of the patients. In contrast, other breast cancer prog-
nostic tests currently in the market not only have 
limited accuracy (sensitivity and specificity , 80%) 
but also limited applicability: they can be admin-
istered only to specific combinations of the afore-
mentioned three hormone receptors, that is to say, 
they can be administered to a small subset of the 
population of the breast cancer patients. Conversely, 
that also means that a large fraction of the women 
with breast cancer cannot avail themselves of those 
prognostic tests, and that, therefore, they cannot be 
enabled to make accurate decisions about treatment 
and management of their disease.
Once again, provided there is further and more 
extensive validation, the clinical significance of our 
prognostic test in the field of breast cancer can be 
summarized in the following. (1) Our prognostic test 
could be applied to all breast cancer patients in spite 
of receptor status, age, or ethnicity. (2) Physicians 
will have the ability to identify with a high degree of 
accuracy both the responders and the non-  responders 
to current chemotherapy at the outset (at the time 
of the biopsy and prior to the commencement of 
  chemotherapy).  (3)  Alternative  therapies  may  be 
provided to those patients identified as non-respond-
ers to chemotherapy at the beginning, saving, thus, 
valuable and critical time, and increasing the prob-
ability of a favorable outcome. (4) In connection 
with  providing  the  non-responders  to  the  T/FAC Prognosis of treatment response in breast cancer
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chemotherapy with effective drugs, our prognostic 
test and the findings of our study pertaining to the 
aforementioned  nine  important  genes  can  assist 
pharmaceutical companies to test and develop new 
analogs of chemotherapeutic agents or new cocktails 
of small molecules that can modulate most, if not 
all, of those nine genes.
In  the  end,  all  of  the  above  may  significantly 
extend  the  survival  of  all  breast  cancer  patients, 
regardless  of  whether  they  are  deemed  responders 
or non-  responders to the current chemotherapy, and 
regardless of their status of the three hormone recep-
tors, their age, or their ethnicity.
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